Groundbreaking studies from the Wellcome Sanger Institute and collaborators have characterized distinct mutational signatures induced by diverse chemotherapy drugs on healthy blood cells, revealing the long-term genetic impact of systemic cancer treatments. Findings show variation in DNA damage by drug class, with platinum-based agents varying in mutation burden. These insights provide a foundation for tailoring chemotherapy regimens to optimize efficacy while minimizing harm to normal tissues.